Valuation: Evotec SE

Market Cap 50Cr 56Cr 46Cr 42Cr 78Cr 5.29TCr 80Cr 547.06Cr 220.52Cr 2.79TCr 209.82Cr 205.34Cr 8.82TCr P/E 2026 *
-2.1x
P/E 2027 * -5.39x
Enterprise Value 61Cr 68Cr 56Cr 51Cr 95Cr 6.43TCr 97Cr 664.59Cr 267.89Cr 3.39TCr 254.9Cr 249.46Cr 11TCr EV / Sales 2026 *
1.03x
EV / Sales 2027 * 1.01x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+2.17%
1 week-1.67%
Current month+0.35%
1 month-4.52%
3 months-18.92%
6 months-47.09%
Current year-48.11%
1 week 2.74
Extreme 2.74
2.99
1 month 2.41
Extreme 2.406
3.12
Current year 2.41
Extreme 2.406
6.73
1 year 2.41
Extreme 2.406
7.16
3 years 2.41
Extreme 2.406
21.69
5 years 2.41
Extreme 2.406
44.94
10 years 2.41
Extreme 2.406
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Exercice

Chief Technology Officer

12,462 0.0070%
04/05/26 Buy 15,510 0.0087%
04/05/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%-1.67%-59.63%-83.87% 56Cr
-2.37%-5.03%+39.49%+62.39% 6.22TCr
-0.15%-0.03%+10.26%+68.08% 5.49TCr
-0.22%+1.64%+19.84%+96.35% 5.53TCr
-3.33%-5.54%+19.39%+35.69% 4.26TCr
-2.45%-2.59%+16.36%+98.45% 4.11TCr
-1.64%+2.32%+219.80%+789.69% 4.03TCr
+0.11%+23.79%+98.98%+83.66% 3.31TCr
+0.21%+1.05%+14.81%+46.96% 3.26TCr
-2.90%+17.12%-42.35%+337.07% 2.4TCr
Average -1.05%+3.87%+33.69%+153.45% 3.87TCr
Weighted average by Cap. -1.37%+2.74%+44.46%+162.15%

Financials

2026 *2027 *
Net sales 59Cr 66Cr 54Cr 49Cr 92Cr 6.24TCr 94Cr 645.16Cr 260.06Cr 3.29TCr 247.44Cr 242.17Cr 10TCr 71Cr 79Cr 65Cr 59Cr 110.7Cr 7.5TCr 112.91Cr 775.28Cr 312.51Cr 3.96TCr 297.35Cr 291.01Cr 13TCr
Net income -23Cr -26Cr -21Cr -19Cr -37Cr -2.47TCr -37Cr -255.81Cr -103.12Cr -1.31TCr -98Cr -96Cr -4.13TCr -4.83Cr -5.4Cr -4.43Cr -4.03Cr -7.55Cr -511.63Cr -7.7Cr -53Cr -21Cr -270.05Cr -20Cr -20Cr -852.95Cr
Net Debt 11Cr 12Cr 9.84Cr 8.95Cr 17Cr 1.14TCr 17Cr 117.53Cr 47Cr 600.17Cr 45Cr 44Cr 1.9TCr 21Cr 24Cr 20Cr 18Cr 33Cr 2.27TCr 34Cr 234.37Cr 94Cr 1.2TCr 90Cr 88Cr 3.78TCr
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
03/26/03 €2.856 +1.71% 4,60,744
02/26/02 €2.808 -0.35% 6,17,167
30/26/30 €2.818 -3.82% 10,80,642
29/26/29 €2.930 -1.35% 7,30,880
28/26/28 €2.970 +3.27% 11,11,092
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.808EUR
Average target price
4.443EUR
Spread / Average Target
+58.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE